실적분석 2026년 8월 10일

BridgeBio Pharma ($BBIO) Q2 2026 Earnings Analysis — Revenue Beats Expectations, Three Pipeline Candidates Enter FDA Review

Earnings Scorecard

Revenue: $244 million (up 120% year-over-year, vs. $220 million estimate) ✅ Beat

EPS (Earnings Per Share): GAAP loss per share of $0.78 (adjusted estimate -$0.58; bases differ, direct comparison not possible)

Guidance: Not provided — no quarterly or annual revenue/EPS outlook figures were included in the press release

Stock Reaction: After-hours +1.28% ($85.75) — as of 08-11 05:59 Korea time

What Went Well

Attruby Revenue: U.S. net product revenue of $222 million led overall growth

Pipeline Progress: All three candidates advanced into FDA review

Financial Flexibility: $720 million in cash and equivalents at end of June, plus $1 billion raised via preferred stock in July

As a rare genetic disease therapy company, the company is scaling both its commercial product and late-stage candidates simultaneously. Attruby grew on the back of a higher mix of patients with no prior treatment experience, and its kidney-protection and real-world data reinforce the differentiation thesis. Commercial and medical-affairs preparation is also underway in lockstep with upcoming approval and launch timelines.

What Fell Short

Continued Losses: Net loss attributable to common shareholders of $152 million in Q2 2026

Rising Costs: Operating expenses climbed to $351 million, a sharp increase year-over-year

Launch Risk: Three upcoming launches depend on regulatory and execution outcomes

Revenue is growing, but heavy R&D and SG&A investment means profitability has not yet arrived. The preferred-stock raise eased the cash position, but dilution concerns and the burden of executing multiple launches remain. It also remains to be seen whether real-world advantages over competing agents translate into prescription share.

What Management Said

Management framed Attruby as the established preferred option for transthyretin amyloid cardiomyopathy patients and stressed the execution milestone of having three pipeline assets in regulatory review at the same time. Leadership also noted that the preferred-stock raise provides the financial capacity to drive all three launches simultaneously.

Market Reaction and What to Watch Next

The modest after-hours buying appears to reflect the combination of a revenue beat and more concrete regulatory review timelines for the late-stage candidates.

Watch whether the November 27, 2026 PDUFA decision for BBP-418 and launch readiness proceed on schedule.

Track the quarterly growth pace of Attruby's net product revenue and the trend in first-line treatment share.

See how the three launch strategies and cost plans are laid out at the October 8 commercial day.